Loredana Storelli

Loredana Storelli

Auto-generated profile, based on publicly available information

Loredana Storelli

Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Radiology
Verified
Journal Article
Closed access
LSLoredana Storelli
Loredana Storelli
MRMaria A. Rocca
Maria A. Rocca
EPElisabetta Pagani
Elisabetta Pagani
WHWim Van Hecke
Wim Van Hecke
MHMark A. Horsfield
Mark A. Horsfield
FGfor the MAGNIMS Study Group
for the MAGNIMS Study Group
From the comparison between the atrophy methods, the identification of a single best software is currently not possible; the selection of atrophy measurement software should be based on whether its performance is satisfactory with regard to the specific requirements of the application. Purpose To compare available methods for whole-brain and gray matter (GM) atrophy estimation in multiple sclerosis (MS) in terms of repeatability (same magnetic resonance [MR] imaging unit) and reproducibility (different system/field strength) for their potential clinical applications. Materials and Methods The softwares ANTs-v1.9, CIVET-v2.1, FSL-SIENAX/SIENA-5.0.1, Icometrix-MSmetrix-1.7, and SPM-v12 were compared. This retrospective study, performed between March 2015 and March 2017, collected data from (a) eight simulated MR images and longitudinal data (2 weeks) from 10 healthy control subjects to assess the cross-sectional and longitudinal accuracy of atrophy measures, (b) test-retest MR images in 29 patients with MS acquired within the same day at different imaging unit field strengths/manufacturers to evaluate precision, and (c) longitudinal data (1 year) in 24 patients with MS for the agreement between methods. Tissue segmentation, image registration, and white matter (WM) lesion filling were als...

1 July 2025 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PPPaolo Preziosa
Paolo Preziosa
EPElisabetta Pagani
Elisabetta Pagani
MMMonica Margoni
Monica Margoni
MRMartina Rubin
Martina Rubin
LSLoredana Storelli
Loredana Storelli
Massimo FilippiMassimo Filippi
Massimo Filippi
The choroid plexus (CP) regulates immune functions and produces most CSF that circulates in the brain parenchyma through perivascular spaces, part of the glymphatic system. In multiple sclerosis (MS), CP enlargement and glymphatic dysfunction are associated with inflammatory activity, clinical disability, and brain damage, but their interrelation is unclear. We investigated whether glymphatic system dysfunction mediates the association between CP enlargement and brain damage in patients with MS. Brain fluid-attenuated inversion recovery, 3-dimensional T1-weighted, diffusion-weighted, and susceptibility-weighted sequences were obtained from 146 patients with MS and 72 healthy controls (HC). Glymphatic function was assessed using the diffusion along the perivascular space (DTI-ALPS) index, and CP volume was measured automatically. Patients with MS showed significantly higher white matter (WM) lesion and CP volumes (p < 0.001), and lower DTI-ALPS index, brain, WM, thalamic, and cortical volumes than HC (p ≤ 0.048). In patients with MS, higher CP volume correlated with a lower DTI-ALPS index (r = -0.305, false discovery rate p value = 0.001). Both measures were associated with higher total, periventricular, and juxtacortical (JC) WM lesion volumes (CP volume: r from 0.285 to 0.340, p-FDR ≤ 0.001; DTI-ALPS index: r from -0.301 to -0.444, p ≤ 0.001), and lower brain, thalamic, cortical, and WM volumes (CP volume: r from -0.246 to -0.405, p-FDR ≤ 0.006; DTI-ALPS index: from 0.269 to 0.497, p-FDR ≤ 0.003). The DTI-ALPS index partially mediated the associations of normalized choroid plexus volume with total, periventricular, and JC T2-hyperintense WM lesion volumes (standardized-β ranging from 0.073 to 0.115, relative effect ranging from 25.2% to 33.6%) and normalized brain, thalamic, cortical, and WM volumes (standardized-β ranging from -0.086 to -0.125, relative effect ranging from 25.3% to 52.7%). In MS, enlarged normalized CP volume may contribute to brain damage accumulation possibly through the promotion of a chronic proinflammatory state and the mediation of glymphatic system dysfunction.

1 June 2023 in Radiology
Verified
Journal Article
Closed access
MRMaria Assunta Rocca
Maria Assunta Rocca
MMMonica Margoni
Monica Margoni
MBMarco Battaglini
Marco Battaglini
AEArman Eshaghi
Arman Eshaghi
JIJeffrey Iliff
Jeffrey Iliff
Massimo FilippiMassimo Filippi
Massimo Filippi
MRI plays a central role in the diagnosis of multiple sclerosis (MS) and in the monitoring of disease course and treatment response. Advanced MRI techniques have shed light on MS biology and facilitated the search for neuroimaging markers that may be applicable in clinical practice. MRI has led to improvements in the accuracy of MS diagnosis and a deeper understanding of disease progression. This has also resulted in a plethora of potential MRI markers, the importance and validity of which remain to be proven. Here, five recent emerging perspectives arising from the use of MRI in MS, from pathophysiology to clinical application, will be discussed. These are the feasibility of noninvasive MRI-based approaches to measure glymphatic function and its impairment; T1-weighted to T2-weighted intensity ratio to quantify myelin content; classification of MS phenotypes based on their MRI features rather than on their clinical features; clinical relevance of gray matter atrophy versus white matter atrophy; and time-varying versus static resting-state functional connectivity in evaluating brain functional organization. These topics are critically discussed, which may guide future applications in the field.

18 October 2022 in Human Brain Mapping
Verified
Journal Article
Open access
Chiara MarziChiara Marzi
Chiara Marzi
ADAlessandro D'Ambrosio
Alessandro D'Ambrosio
SDStefano Diciotti
Stefano Diciotti
ABAlvino Bisecco
Alvino Bisecco
MAManuela Altieri
Manuela Altieri
TNThe Inni Network
The Inni Network
Many patients with multiple sclerosis (MS) experience information processing speed (IPS) deficits, and the Symbol Digit Modalities Test (SDMT) has been recommended as a valid screening test. Magnetic resonance imaging (MRI) has markedly improved the understanding of the mechanisms associated with cognitive deficits in MS. However, which structural MRI markers are the most closely related to cognitive performance is still unclear. We used the multicenter 3T‐MRI data set of the Italian Neuroimaging Network Initiative to extract multimodal data (i.e., demographic, clinical, neuropsychological, and structural MRIs) of 540 MS patients. We aimed to assess, through machine learning techniques, the contribution of brain MRI structural volumes in the prediction of IPS deficits when combined with demographic and clinical features. We trained and tested the eXtreme Gradient Boosting (XGBoost) model following a rigorous validation scheme to obtain reliable generalization performance. We carried out a classification and a regression task based on SDMT scores feeding each model with different combinations of features. For the classification task, the model trained with thalamus, cortical gray matter, hippocampus, and lesions volumes achieved an area under the receiver operating characteristic curve of 0.74. For the regression task, the model trained with cortical gray matter and thalamus volumes, EDSS, nucleus accumbens, lesions, and putamen volumes, and age reached a mean absolute error of 0.95. In conclusion, our results confirmed that damage to cortical gray matter and relevant deep and archaic gray matter structures, such as the thalamus and hippocampus, is among the most relevant predictors of cognitive performance in MS.

12 February 2018 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
FEFederica Esposito
Federica Esposito
LFL. Ferrè
L. Ferrè
FCF. Clarelli
F. Clarelli
MRM. A. Rocca
M. A. Rocca
GSG. Sferruzza
G. Sferruzza
VMV. Martinelli
V. Martinelli

28 March 2016 in Journal of Neuroimaging
Verified
Journal Article
Closed access
PDF file
MHMark A. Horsfield
Mark A. Horsfield
MRMaria A. Rocca
Maria A. Rocca
EPElisabetta Pagani
Elisabetta Pagani
LSLoredana Storelli
Loredana Storelli
PPPaolo Preziosa
Paolo Preziosa
Massimo FilippiMassimo Filippi
Massimo Filippi